Pramiracetam
From Wikipedia, the free encyclopedia
 |
|
|---|---|
 |
|
| Systematic (IUPAC) name | |
| N-[2-(diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide | |
| Clinical data | |
| Trade names | Neupramir, Pramistar, Remen |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | Unscheduled (US) |
| Routes | Oral |
| Pharmacokinetic data | |
| Half-life | 4.5-6.5 hours |
| Identifiers | |
| CAS number | 68497-62-1  |
| ATC code | N06BX16 |
| PubChem | CID 51712 |
| ChemSpider | 46801 |
| UNII | 4449F8I3LE  |
| ChEMBL | CHEMBL159776 |
| Chemical data | |
| Formula | C14H27N3O2 |
| Mol. mass | 269.383 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
Pramiracetam is a nootropic dietary supplement derived from piracetam, and is more potent (i.e. lower dosage is used). It belongs to the racetam family of nootropics.
Pramiracetam was developed by Parke-Davis based on Piracetam, and is claimed to be 8-30 times stronger than Piracetam. It goes by the trade name Remen (Parke-Davis), Neupramir (Lusofarmaco) or Pramistar (Firma).[1]
[edit] References
- ^ Axel Kleemann, Jürgen Engel, Bernd Kutscher und Dietmar Reichert: Pharmaceutical Substances, 4. Edition (2000), ISBN 978-1-58890-031-9
[edit] External links
|
|
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
